Exploring a new boron-based treatment for kidney cancer
Assessment of a recently developed boron-based HIF inhibitor as a prospective therapy for renal cell carcinoma (RCC)
This study is looking at a new treatment that could help people with clear cell kidney cancer by blocking a specific pathway that makes the cancer grow, and they're testing different versions of a compound to find the best one for this purpose.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Missouri Kansas City NIH-funded |
| Lab location | 1 site (Kansas City, United States) |
| Project ID | NIH-10947752 on NIH RePORTER |
What this research studies
This research investigates a novel boron-based inhibitor that targets the hypoxia-inducible factor (HIF) pathway, which is often overactive in clear cell renal cell carcinoma (RCC). By understanding how this inhibitor works and its effects on cancer cells, the researchers aim to develop a more effective therapy for RCC. The study involves testing various analogs of a compound called honokiol to see which ones best inhibit the HIF pathway and evaluating their effectiveness in a mouse model of RCC. If successful, this could lead to new treatment options for patients with this type of kidney cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with clear cell renal cell carcinoma, particularly those with advanced disease.
Not a fit: Patients with other types of kidney cancer or those who are not eligible for experimental therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new and effective therapy for patients suffering from renal cell carcinoma.
How similar studies have performed: Previous research has shown promise in targeting the HIF pathway for cancer treatment, indicating that this approach could be effective.
Where this research is happening
Kansas City, United States
- University of Missouri Kansas City — Kansas City, United States (Active)
Researchers
- Principal investigator: Mukherji, Mridul — University of Missouri Kansas City
- Study coordinator: Mukherji, Mridul
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.